title: Identification of chromosomal errors in human preimplantation embryos with oligonucleotide DNA microarray.
abstract: A previous study comparing the performance of different platforms for DNA microarray found that the oligonucleotide (oligo) microarray platform containing 385K isothermal probes had the best performance when evaluating dosage sensitivity, precision, specificity, sensitivity and copy number variations border definition. Although oligo microarray platform has been used in some research fields and clinics, it has not been used for aneuploidy screening in human embryos. The present study was designed to use this new microarray platform for preimplantation genetic screening in the human. A total of 383 blastocysts from 72 infertility patients with either advanced maternal age or with previous miscarriage were analyzed after biopsy and microarray. Euploid blastocysts were transferred to patients and clinical pregnancy and implantation rates were measured. Chromosomes in some aneuploid blastocysts were further analyzed by fluorescence in-situ hybridization (FISH) to evaluate accuracy of the results. We found that most (58.1%) of the blastocysts had chromosomal abnormalities that included single or multiple gains and/or losses of chromosome(s), partial chromosome deletions and/or duplications in both euploid and aneuploid embryos. Transfer of normal euploid blastocysts in 34 cycles resulted in 58.8% clinical pregnancy and 54.4% implantation rates. Examination of abnormal blastocysts by FISH showed that all embryos had matching results comparing microarray and FISH analysis. The present study indicates that oligo microarray conducted with a higher resolution and a greater number of probes is able to detect not only aneuploidy, but also minor chromosomal abnormalities, such as partial chromosome deletion and/or duplication in human embryos. Preimplantation genetic screening of the aneuploidy by DNA microarray is an advanced technology used to select embryos for transfer and improved embryo implantation can be obtained after transfer of the screened normal embryos.
authors.affiliation: Houston Fertility Institute, Houston, Texas, United States of America.
authors.forename: Lifeng
authors.initials: L
authors.lastname: Liang
authors.forename: Cassie T
authors.initials: CT
authors.lastname: Wang
authors.forename: Xiaofang
authors.initials: X
authors.lastname: Sun
authors.forename: Lian
authors.initials: L
authors.lastname: Liu
authors.forename: Man
authors.initials: M
authors.lastname: Li
authors.forename: Craig
authors.initials: C
authors.lastname: Witz
authors.forename: Daniel
authors.initials: D
authors.lastname: Williams
authors.forename: Jason
authors.initials: J
authors.lastname: Griffith
authors.forename: Josh
authors.initials: J
authors.lastname: Skorupski
authors.forename: Ghassan
authors.initials: G
authors.lastname: Haddad
authors.forename: Jimmy
authors.initials: J
authors.lastname: Gill
authors.forename: Wei-Hua
authors.initials: WH
authors.lastname: Wang
mesh_terms: D001755:Blastocyst / Q000378:metabolism*; D002869:Chromosome Aberrations; D010064:Embryo Implantation / Q000502:physiology; D005260:Female; D006801:Humans; D017404:In Situ Hybridization, Fluorescence / Q000379:methods; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods*; D011247:Pregnancy; D019836:Preimplantation Diagnosis / Q000379:methods*